WO2010104309A2 - Compositions for preventing or improving gastrointestinal diseases - Google Patents
Compositions for preventing or improving gastrointestinal diseases Download PDFInfo
- Publication number
- WO2010104309A2 WO2010104309A2 PCT/KR2010/001450 KR2010001450W WO2010104309A2 WO 2010104309 A2 WO2010104309 A2 WO 2010104309A2 KR 2010001450 W KR2010001450 W KR 2010001450W WO 2010104309 A2 WO2010104309 A2 WO 2010104309A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastric
- composition
- extract
- ulcer
- licorice
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 44
- 230000006378 damage Effects 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 19
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 17
- 208000000718 duodenal ulcer Diseases 0.000 claims abstract description 5
- 230000000391 smoking effect Effects 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 43
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 41
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 40
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 40
- 229940010454 licorice Drugs 0.000 claims description 40
- 241000202807 Glycyrrhiza Species 0.000 claims description 35
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 210000001156 gastric mucosa Anatomy 0.000 claims description 15
- 210000002784 stomach Anatomy 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 12
- 208000025865 Ulcer Diseases 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 11
- 208000007882 Gastritis Diseases 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 8
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 239000000321 herbal drug Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 244000299790 Rheum rhabarbarum Species 0.000 claims 2
- 239000000287 crude extract Substances 0.000 claims 2
- 244000269722 Thea sinensis Species 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000000689 peptic esophagitis Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 208000027418 Wounds and injury Diseases 0.000 abstract description 20
- 241000411851 herbal medicine Species 0.000 abstract description 18
- 208000014674 injury Diseases 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 description 42
- 239000012676 herbal extract Substances 0.000 description 38
- 238000011282 treatment Methods 0.000 description 31
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 26
- 241000219061 Rheum Species 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 23
- 238000009472 formulation Methods 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 13
- 244000265736 Nelumbo pentapetala Species 0.000 description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000000767 anti-ulcer Effects 0.000 description 9
- 229960000905 indomethacin Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000027119 gastric acid secretion Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 6
- 229960001259 diclofenac Drugs 0.000 description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 210000004211 gastric acid Anatomy 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940069445 licorice extract Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000013222 sprague-dawley male rat Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000282376 Panthera tigris Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001775 anti-pathogenic effect Effects 0.000 description 2
- -1 anti-ulcer Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000218203 Coptis japonica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003431 anti-prostaglandin Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Definitions
- the present invention relates to a composition for the prevention or treatment of gastrointestinal diseases, and more particularly, to a composition for the prevention or treatment of gastrointestinal diseases, the effect of which is significantly improved by including a combination of herbal ingredients known to be effective in the treatment of conventional gastrointestinal diseases. will be.
- Inflammation with erosion, redness, bleeding, and edema occurs when gastric acid secretion is increased or gastric mucosal protective layer is damaged by various factors, and this inflammatory lesion is limited to the gastric mucosa. It is called gastric ulcer when it is severely damaged and penetrates the gastric mucosa and damages the submucosal tissue and muscle layer.
- the duodenum which is directly connected to the stomach, may cause inflammation and duodenal ulcer by similar factors, and gastric ulcer and duodenal ulcer are collectively referred to as peptic ulcer.
- gastritis and gastric ulcers can be broadly divided into pathological excesses of attack factors such as excessive gastric acid secretion and weakening of protective factors that protect gastric mucosal cells from gastric acid attack.
- Gastric ulcer drugs have been developed and used as inhibitors and enhancers of defense factors.
- Representative attack factors include gastric acid, pepsin, alcohol and smoking, stress and nonsteroidal anti-inflammatory drugs, infections of Helicobacter pylori ( Helicobacter pylori ).
- Factors that weaken the defensive factors include loss of structure and form of the gastric mucosa, decreased mucus secretion, decreased bicarbonate secretion, and decreased prostaglandin production.
- gastric acid secretion In order to treat inflammation and ulcer of stomach and duodenum caused by attack factors, gastric acid secretion, mucous secretion promotion, gastric mucosal epithelial cell regeneration, inhibition of Helicobacter pylori proliferation and administration of anti-inflammatory drugs are required.
- the most representative agents for the treatment of gastritis and gastric ulcers are drugs such as antacid, H2-receptor antagonist (H2-RA), proton pump inhibitor (PPI) and gastric mucosa protector for acid secretion.
- H2-RA H2-receptor antagonist
- PPI proton pump inhibitor
- gastric mucosa protector for acid secretion A combination of these drugs and antibiotics is being used to eliminate Helicobacter pylori.
- these gastric acid secretion inhibitors have a high recurrence rate after the end of the drug administration [Drug Intell. Clin.
- Gastric mucosal protection agents are known to regenerate mucosal tissue to a similar level as normal to compensate for the shortcomings of these fast-acting gastric acid secretion inhibitors (Folia Pharmacol. Japan, 92: 389, 1988) and are an important part of the treatment of gastritis. .
- gastric mucosa protective agents have the disadvantage that they are fast-acting, high-dose, and have to be taken for a relatively long time.
- Korean Patent Laid-Open Publication No. 1996-0021054 discloses a composition for treating gastrointestinal diseases comprising mugwort leaf extract as an active ingredient, and the composition for treating gastrointestinal diseases is commercialized as styrene tablets and sold and prescribed as a successful natural gastritis treatment.
- Coptis Rhizoma is a rhizome ( Coptis japonica ), a perennial herbaceous plant of the Ranunculuaceae, and a root stem that almost eliminates the roots of the same plant (9 KP, 2007). Dry it in the sun and remove the cork layer.
- the main pharmacological action of Huangshan is known as anti-inflammatory, anti-ulcer, anti-cancer, anti-radiation, anti-microbial and anti-pathogenic action.
- Licorice (Glycyrrhizae Radix) is the same as or without the roots and cuticles of perennial herbaceous ( Glycyrrhiza uralensis ) and Glycyrrhiza glabra or other similar plants. 2007], roots are cut in autumn to remove stems, twigs and beard roots, cut to length and sun-dried.
- the main pharmacological actions of licorice are known as a wide range of detoxification, antidiuresis, antitussive expectoration, anti-inflammatory, anti-allergic, anti-ulcer, and interpolation.
- each of the shiho, rhubarb, and licorice are known to have anti-ulcer activity, they do not have sufficient effects to be used as a medicament for preventing or treating gastrointestinal diseases, and a composition for preventing or treating gastrointestinal diseases having better effects. Development is needed.
- the present inventors recognized the necessity of developing a composition for the prevention or treatment of gastrointestinal diseases caused by mucosal damage of the stomach or duodenum, and studied the composition for the prevention or treatment of gastrointestinal diseases with superior effects.
- the present invention has been found to have a significant gastrointestinal disease prevention and treatment effect when compared to the case of including a combination of two or more of, and licorice, each of which alone is unpredictable.
- compositions for the prevention or treatment of effective gastrointestinal diseases comprising a combination of herbal medicines as an active ingredient.
- Another object of the present invention to provide a pharmaceutical and health functional food comprising the composition for the prevention or treatment of gastrointestinal diseases.
- compositions for the prevention or treatment of gastrointestinal diseases including two or more herbal drugs selected from the group consisting of Bupleuri Radix, Coptidis Rhizoma, and Glycyrrhizae Radix.
- the present invention also provides a medicament comprising the composition and a pharmaceutically acceptable carrier or additive.
- the present invention also provides a dietary supplement comprising the composition and a food acceptable carrier or additive.
- composition for the prevention or treatment of gastrointestinal diseases according to the present invention is unpredictable to those skilled in the art in the prevention or treatment effect of gastrointestinal diseases as a result of combining two or more of Siho, rhubarb, and licorice, which are known to have an anti-ulcer effect. It turned out that there was remarkable effect of degree and was completed.
- the present invention provides a composition for preventing or treating gastrointestinal diseases, including two or more herbal drugs selected from the group consisting of Buleuri Radix, Cooptidis Rhizoma, and Licorice (Glycyrrhizae Radix). .
- Shiho, rhubarb, and licorice in the composition is not particularly limited in the combination ratio thereof, but may preferably comprise a ratio of 10-30 parts by weight of sulfur and 10-30 parts by weight of licorice with respect to 100 parts by weight of shiho. .
- the herbal medicines constituting the composition of the present invention are obviously equivalent to those in the art, and include all the herbal medicines that can be used for the prevention or treatment of gastrointestinal diseases.
- the shiho, rhubarb, and licorice each may be contained in the composition as a solvent extract of the herbal medicine, and may be contained in a pulverized product of the herbal medicine, a pulverized product of the dried herbal medicine, and the like.
- Solvent extract of the crude drug can be extracted by each of the herbal separately or together water, an organic solvent, or a combination thereof, as the organic solvent is C 1 -C 4 alcohol, acetone, chloroform, methylene chloride, ether, Ethyl acetate, hexane, or a combination thereof may be used, but is not limited thereto.
- Examples of C 1 -C 4 alcohols include methanol, ethanol, propanol and butanol, and ethanol is most preferred.
- the solvent extracts of shiho, rhubarb, and licorice may be prepared by any extraction method known to those skilled in the art of herbal extraction, but 10 to 80 at an extraction temperature of 10 ° C. to 80 ° C., preferably room temperature (25 ° C.). Using extraction methods such as hot water extraction, cold sediment extraction, reflux cooling extraction or ultrasonic extraction for 2 hours to 3 days, preferably, extraction may be carried out one to five times in succession by cold extraction. .
- the solvent extract thus obtained can be obtained as a final extract by filtration under reduced pressure and the filtration extract is concentrated under reduced pressure at 20 to 100 ° C., preferably at room temperature (25 ° C.) with a rotary evaporator and lyophilized.
- the composition comprising a combination of two or more of Siho, rhubarb, and licorice according to the present invention is effective in preventing or treating gastrointestinal diseases, and the gastrointestinal diseases include all gastrointestinal diseases known to be caused by mucosal damage of the stomach and twelve limbs. .
- the gastrointestinal disease may be caused by various causes such as alcohol, smoking, stress, drugs, or a combination thereof, but is not limited thereto.
- Drugs that cause the gastrointestinal disorders include, but are not limited to, nonsteroidal anti-inflammatory agents, steroids, and the like.
- the nonsteroidal anti-inflammatory agents are typically indomethacin, diclofenac, aspirin, acetaminophen, ibuprofen, meloxycamp, naproxen and the like.
- the prophylactic or therapeutic effect of such gastrointestinal diseases of the compositions according to the invention was demonstrated in the following examples. Specifically, as a result of administering to a rat a composition comprising a composition comprising a combination of two or more of sea lakes, yellow lotus, and licorice according to the present invention and causing gastric ulceration by alcohol, water restraint, or nonsteroidal anti-inflammatory drugs (NSAIDs), Compared to the non-administered group (control group) of the composition according to the present invention, the ulcer index was significantly lower in the administration group, and it was confirmed to show a remarkably superior effect compared to styrene tablets widely used as a conventional herbal medicine for treating gastrointestinal diseases.
- NSAIDs nonsteroidal anti-inflammatory drugs
- the preventive effect of after inducing direct ulceration of gastric tissue by acetic acid, a long term administration of a composition comprising a combination of two or more of sea tiger, yellow lotus, and licorice according to the present invention is followed by anti-ulcer action and mucosal regeneration effect by prostaglandins.
- the gastrointestinal disease treatment index was remarkably excellent in the administration group compared to the non-administration group (control group) of the composition according to the present invention, and showed a remarkably superior effect compared to the styrene tablet widely used as a conventional herbal medicine for treating gastrointestinal diseases It has been confirmed that the therapeutic effect of gastrointestinal diseases has been proved.
- the respective doses are the same.
- the composition comprising two or more herbal medicines according to the present invention when administered as compared to the case of administering each herbal extract alone, the effect of inhibiting gastric damage in rats is higher, thus preventing and treating gastrointestinal diseases. It has been proven to have synergistic action.
- the case comprising all three lakes, yellow lotuses, and licorice has not only a synergistic effect, but also a composition containing two wild herbs, respectively.
- composition according to the present invention contains herbal medicines that have been proven to be safe while being used for a very long time, and thus have little toxicity and side effects, and thus can be used safely for long-term treatment or for long-term treatment of gastrointestinal diseases.
- the present invention provides a medicament comprising the composition according to the present invention, and a pharmaceutically acceptable carrier or additive.
- the drug may be administered to various mammals including rats, mice, livestock, humans, etc. by various routes, for example oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injections. May be administered.
- the medicament may be formulated in conventional pharmaceutical formulations known in the art.
- the medicament may be formulated and administered in any dosage form including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative agents, but preferably liquids, suspensions, powders, granules, It may be formulated in oral dosage forms such as tablets, capsules, pills, emulsions, syrups, aerosols, or extracts.
- each of the above formulations it may be prepared by the addition of a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation.
- a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation.
- one or more of a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative may be used as the carrier, and as an additive, flavors, vitamins, and antioxidants may be used.
- a diluent a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative
- flavors, vitamins, and antioxidants may be used.
- One or more types can be selected and used out of them.
- the carrier and the additive may be any pharmaceutically acceptable, specifically, as a diluent, lactose, dextrose, sucrose, corn starch, soybean oil, microcrystalline cellulose, sorbitol, xylitol, or mannitol, magnesium stearate as a lubricant, As talc and a binder, polyvinylpyrrolidone or hydroxypropyl cellulose is preferable.
- natural flavors such as plum, lemon, pineapple, herb
- natural pigments such as fruit juice, chlorophyllin, flavonoids, fructose, honey, sugar alcohol, sugar Sweetening ingredients such as, or may be used by mixing an acidulant such as citric acid, sodium citrate.
- aqueous solutions there are sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
- non-aqueous solvents and suspending agents propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
- injectable esters such as ethyl oleate and the like
- suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol gelatin and the like can be used.
- the drug can be appropriately added to or lowered the mixing ratio of the constituent herb appropriately within the range that effectively maintains the therapeutic or prophylactic effect of gastrointestinal diseases, 0.01-80% by weight of the herbal component constituting the composition according to the present invention, Preferably 1-50% by weight.
- the pharmaceutical product may contain 0.01-10 g / kg / day, preferably 1-5 g / kg / day, based on the dry powder of the solvent extract. It may be administered once or several times a day, and may be appropriately increased or decreased depending on the age, sex, weight, diet, excretion rate, and other drugs currently being taken. Therefore, the pharmaceutical preparation according to the present invention is to be prepared in consideration of the range of effective amount, and the dosage unit formulation formulated in this way is a specialized dosage according to the judgment of experts and the needs of the individual to monitor or observe the administration of the drug as necessary It may be administered several times at intervals using a method or at regular intervals.
- composition according to the present invention can also be used as a raw material of health functional food for the prevention or treatment of gastrointestinal diseases.
- the present invention provides a dietary supplement comprising the composition according to the present invention, and a food acceptable carrier or additive.
- Health functional foods defined in the present invention is a health function prescribed in the Food and Drug Administration Notice 2008-72 is sufficiently established that the newly defined functional and safety for the human body through the Act on Health Functional Foods amended in 2008 It means that it is a health functional food as listed in the regulations on the recognition of food functional ingredients.
- Such dietary supplements can be formulated in the formulation of conventional dietary supplements known in the art.
- the dietary supplement may be prepared, for example, as a powder, granules, tablets, pills, capsules, suspensions, emulsions, syrups, dips, liquids, extracts, gums, teas, jelly, or beverages.
- any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared.
- the dietary supplement may comprise 0.01 to 15% by weight, preferably 0.2 to 10% by weight of the total weight of the food ingredients constituting the composition according to the present invention, based on 100 mL when prepared as a beverage In the range of 0.1 to 30 g, preferably 0.2 to 5 g.
- the beverage may further contain other ingredients in addition to the herbal ingredients, and may further contain various flavors or natural carbohydrates, etc. that are commonly used in beverages.
- the natural carbohydrates include conventional sugars such as monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), polysaccharides (e.g., dextrin, cyclodextrin, etc.) and xylitol, sorbitol, erythritol, etc. Sugar alcohols may be contained.
- the flavoring agent may contain natural flavoring agents (e.g., taumartin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.).
- natural flavoring agents e.g., taumartin, stevia extract, etc.
- synthetic flavoring agents e.g., saccharin, aspartame, etc.
- the proportion of the natural carbohydrate is preferably contained in about 1 to 20 g, preferably about 5 to 12 g per 100 mL of beverage.
- the drug and the health supplement according to the present invention may be administered simultaneously with two or more combinations of Shiho, rhubarb, and licorice, which are included as active ingredients, but the extent to which the composition can prevent or treat gastrointestinal diseases It may be administered sequentially at predetermined intervals within. If two or more combinations of shiho, rhubarb and licorice are to be administered at predetermined intervals, each active ingredient may be formulated in a separate, separate formulation. When two or more combinations of shiho, rhubarb, and licorice are to be administered simultaneously, they may be formulated in a uniformly mixed form in one formulation, or may be formulated in separate formulations and then administered simultaneously.
- the composition according to the present invention comprises a combination of two or more of shiho, yellow lotus, and licorice, thereby having a remarkably effective effect in the treatment of gastrointestinal diseases associated with mucosal damage of the gastrointestinal or duodenal ulcer. It is preferable because it is composed of natural materials, so it has little toxicity to human body and little risk of recurrence. Therefore, the composition according to the present invention can be used as a medicine or health functional food for the prevention or treatment of various gastrointestinal diseases caused by alcohol, stress, smoking, or drugs.
- FIG 1 and 2 are photographs of the herbal extract prepared according to one embodiment of the present invention to observe the inhibitory effect of gastric damage caused by diclofenac.
- Figure 3 is a photograph of the herbal extract prepared according to an embodiment of the present invention to observe the effect of preventing gastric damage caused by indomethacin intraperitoneal administration through tissue staining.
- Figure 4 is a photograph of the herbal extract prepared according to an embodiment of the present invention observed the effect of treating subacute gastric injury induced by acetic acid through tissue staining.
- Ethanol causes bleeding and swelling of the submucosal muscle layer by direct stimulation of the gastric mucosa, causing temporary ischemia, causing necrosis of cells, reducing the amount of ATP in the mucosa and congestion of microcirculation.
- Hydrochloric acid stimulates gastrointestinal motility, causing acute gastritis.
- mice with no specific pathogen were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment.
- Each group was divided into 5 animals, and each animal was orally administered at a dose of 100 mg / kg or 200 mg / kg to the fasted animal for 20 hours under free water intake and 150 mM after 1 hour.
- 60% ethanol prepared with HCl solution was orally administered 1 mL per horse and gastric injury was induced for 1 hour.
- the rats were sacrificed by suffocation with CO 2 , the stomach was extracted, fixed with 1% formalin solution, incised and spread along the Taiwanese area, and then the gastrointestinal damage was visually observed, the length of the gastric ulcer index was measured. Calculated.
- a composite extract comprising each of the extracts of shiho, rhubarb and licorice prepared in Comparative Examples 1-3 and two herbal extracts of Example 1-3, and both shiho, rhubarb and licorice of Example 4 was prepared.
- the test groups were compared for drug efficacy against alcoholic acute gastritis. Water was administered as a control and the experimental results are shown in Table 1 below.
- Example 1 the administration of two or more complex extracts of shiho, rhubarb, and licorice as in Example 1-3 is significantly superior to the case of administration of a single extract of shiho, rhubarb and licorice respectively. It was found to have an anti-ulcer effect.
- Example 4 the case of administering the composite extracts of Shiho, Huang lotus, and licorice, as in Example 4, as well as the case of administering a single extract of Shiho, Huang lotus and licorice, as well as two or more complex extracts It was found to have a remarkably good anti-ulcer effect.
- the two or more herbal extracts of shiho, rhubarb, and licorice according to the present invention have a significant preventive effect against gastrointestinal diseases.
- the herbal extract of Example 4 has a significantly better prevention of gastrointestinal diseases than styrene currently used for the treatment of gastrointestinal disorders against the gastric mucosa damaged by ethanol.
- mice Seven week-old male Sprague-Dawley rats with no specific pathogens (SPF) were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Each group was divided into 5 animals, and the animals were orally administered to the fasted experimental animals for 20 hours under free water consumption, and 30 minutes later, they were placed in a stress cage so that the scalp was submerged.
- SPF pathogens
- Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy.
- styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
- water was administered as a control to compare the drug efficacy.
- the herbal extract of Example 4 has a significantly better prevention or treatment efficacy of gastrointestinal diseases, compared to the styrene tablets currently used for the treatment of gastrointestinal diseases, on gastric mucosa damaged by immersion restraint. It can be seen that.
- Nonsteroidal anti-inflammatory agents inhibit the biosynthesis of prostaglandin (PG), leading to damage of the gastric mucosa.
- PG prostaglandin
- the preventive effect of gastric injury by diclofenac administration was confirmed.
- Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy.
- styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
- water was administered as a control to compare drug efficacy.
- the herbal extract of Example 4 has a remarkably superior therapeutic effect against acute gastric mucosal damage caused by diclofenac compared to styrene tablets currently used as a gastrointestinal disease treatment.
- the gastric wall damaged by diclofenac was inhibited by administering the herbal extract of Example 4 and Comparative Example 4 (styrene tablets), and the herbal extract of Example 4 was It has been confirmed that there is a concentration-dependent gastric damage inhibitory effect.
- the drug was orally administered once daily for 6 days, followed by fasting for 24 hours, followed by intraperitoneal administration of indomethacin at a concentration of 70 mg / kg, and gastric injury for 7 hours.
- the rats were sacrificed and the stomach was extracted, fixed with 1% formalin solution, incised and extended along the Taiwanese area, and then the gastric ulcer was visually observed and the length of the gastric ulcer was measured and evaluated by the gastric ulcer index.
- Blood of test animals was collected and analyzed for the content of nitric oxide (NO), superoxide dismutase (SOD) and epidermal growth factor (EGF).
- NO nitric oxide
- SOD superoxide dismutase
- EGF epidermal growth factor
- Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy.
- styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
- water was administered as a control to compare drug efficacy.
- paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 3.
- the herbal extract of Example 4 has a significantly superior preventive effect compared to the styrene tablets currently used as a gastrointestinal disorder treatment against gastric mucosal damage caused by intraperitoneal indomethacin administration. have.
- mice with no specific pathogen were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment. Subdivided into 5 groups for each group, anesthetized with ether under an unfastened stomach, open the stomach, and exposed to the stomach, using a microliter syringe. Inject and suture the abdomen with cotton yarn.
- Induce ulcers for 3 days then orally administer the drug once a day for 14 days, fast for 24 hours after the final dose, suffocate with CO 2 , sacrifice the rats, extract the stomach and fix with 1% formalin solution After incision and unfolding, gross damage was observed visually, the length of the gastric ulcer was measured and evaluated by the gastric ulcer index and recorded. Blood of each test animal was collected and analyzed for the content of NO, SOD and EGF in the blood.
- Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy.
- styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
- water was administered as a control to compare the drug efficacy.
- paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 4.
- the herbal extract of Example 4 has an excellent therapeutic effect on the subtype of gastric mucosal damage caused by acetic acid.
- gastric wall (B) damaged by acetic acid compared to normal group (A) was treated by administering the herbal extracts (E, F) and Comparative Example 1 (C, D) of Example 4. It can be confirmed that the herbal extract of Example 4 has a concentration-dependent gastric damage inhibitory effect.
- Tablets for oral administration using the herbal extract prepared in Example 4 were prepared by granulation using wet granulation and dry granulation with the following composition, followed by tableting to prepare tablets.
- Example 4 Using the herbal extract prepared in Example 4 to fill a gelatin capsule with the following composition to prepare a capsule.
- Example 4 Using the herbal extract prepared in Example 4 to prepare a liquid formulation with the following composition.
- Example 4 Using the herbal extract prepared in Example 4 was mixed in the following composition and filled in an airtight fabric to prepare a powder.
- Water, walnut oil and vinegar may be used instead of honey.
- the hot honey prepared as described above is kneaded by adding 5 g of the herbal extract prepared in Example 4, and then the dough is molded into a ring of equal size by using an artificial or a machine to prepare a pill.
- the prepared pills are dried in a cool and dry place and then stored in a cool and airtight place.
- a suspending agent is prepared according to a conventional method for preparing a suspending agent by mixing syrup, sugar, honey, or D-mannitol.
- Chewing gum is prepared using a conventional method using the herbal extract prepared in Example 4 in the following composition and content.
- Example 4 Using the herbal extract prepared in Example 4 to prepare a beverage using conventional methods in the following composition and content.
- Example 4 Using the herbal extract prepared in Example 4 to prepare a candy using a conventional method with the following composition and content.
- a mixture of 20% herbal extract and 80% crystalline lactitol is diluted with purified water and placed in a sauce pen.
- the batch is first heated on a hot plate until all material is solubilized, then the batch is transferred to a vacuum cooker and further heated.
- the formed blend forms a viscous mass even at relatively low temperatures.
- the syrup is then transferred from the cooker to the thick plate and cured until a suitable tissue is formed for drop rolling. The cured mass is fed through a drop roller. Once imprinted, the candy has an acceptable quality.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (9)
- 시호(Bupleuri Radix), 황련(Coptidis Rhizoma), 및 감초(Glycyrrhizae Radix)로 구성된 그룹에서 선택된 둘 이상의 생약을 포함하는 위장질환의 예방 또는 치료용 조성물. A composition for preventing or treating gastrointestinal diseases, comprising two or more herbal drugs selected from the group consisting of Bupleuri Radix, Cooptidis Rhizoma, and Glycyrrhizae Radix.
- 제 1 항에 있어서, 상기 시호 100 중량부에 대해 황련 10-30 중량부, 감초 10-30 중량부로 포함하는 것을 특징으로 하는 조성물. The composition according to claim 1, comprising 10-30 parts by weight of rhubarb and 10-30 parts by weight of licorice with respect to 100 parts by weight of the seahawk.
- 제 1 항에 있어서, 상기 시호, 황련, 및 감초는 각각 생약 자체의 분쇄물, 생약의 건조 분쇄물, 또는 물, C1-C4 알콜, 및 이들이 조합으로 구성된 그룹에서 선택된 용매의 조추출물인 것을 특징으로 하는 조성물. The method according to claim 1, wherein the shiho, rhubarb, and licorice are each a crude extract itself, a dry extract of the crude drug, or a crude extract of a solvent selected from the group consisting of water, C 1 -C 4 alcohols, and combinations thereof. A composition, characterized in that.
- 제 1 항에 있어서, 상기 위장질환은 알코올, 흡연, 스트레스, 약물, 또는 이들이 조합에 의해 유발되는 위 또는 십이지장의 점막 손상인 것을 특징으로 하는 조성물. The composition of claim 1, wherein the gastrointestinal disease is mucosal damage of the stomach or duodenum caused by alcohol, smoking, stress, drugs, or a combination thereof.
- 제 1 항에 있어서, 상기 위장질환은 위염, 위궤양, 십이지장궤양, 졸링거-엘리슨증후군, 역류성식도염, 수술후궤양, 또는 위점막의 미란, 출혈, 발적, 또는 부종인 것을 특징으로 하는 조성물. The composition of claim 1, wherein the gastrointestinal disease is gastritis, gastric ulcer, duodenal ulcer, Solinger-Elison syndrome, reflux esophagitis, postoperative ulcer, or erosion, bleeding, redness, or edema of the gastric mucosa.
- 제 1 항 내지 제 5 항 중 어느 한 항에 따른 조성물 및 약제학적으로 허용 가능한 담체 또는 첨가제를 포함하는 의약품. A pharmaceutical product comprising the composition according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier or additive.
- 제 6 항에 있어서, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽제, 액제, 에어로졸, 엑스제, 주사제, 경피 투여제, 또는 좌제의 형태인 것을 특징으로 하는 의약품. The pharmaceutical product according to claim 6, which is in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, injection, transdermal or suppository.
- 제 1 항 내지 제 5 항 중 어느 한 항에 따른 조성물 및 식품학적으로 허용 가능한 담체 또는 첨가제를 포함하는 건강기능식품. A health functional food comprising the composition according to any one of claims 1 to 5 and a food acceptable carrier or additive.
- 제 8 항에 있어서, 상기 액제, 현탁제, 산제, 과립제, 정제, 캡슐제, 환제, 엑스제, 차, 젤리, 또는 음료의 형태인 것을 특징으로 하는 건강기능식품.The health functional food according to claim 8, which is in the form of a liquid, suspension, powder, granule, tablet, capsule, pill, extract, tea, jelly, or beverage.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800139052A CN102365091A (en) | 2009-03-13 | 2010-03-09 | Compositions for preventing or improving gastrointestinal diseases |
BRPI1009105A BRPI1009105A2 (en) | 2009-03-13 | 2010-03-09 | compositions for preventing or ameliorating gastrointestinal disorders |
RU2011141504/15A RU2500416C2 (en) | 2009-03-13 | 2010-03-09 | Compositions for preventing or relieving gastrointestinal diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0021867 | 2009-03-13 | ||
KR1020090021867A KR101099004B1 (en) | 2009-03-13 | 2009-03-13 | A composition for preventing or treating a gastrointestinal disease |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2010104309A2 true WO2010104309A2 (en) | 2010-09-16 |
WO2010104309A3 WO2010104309A3 (en) | 2011-01-06 |
WO2010104309A9 WO2010104309A9 (en) | 2011-02-24 |
Family
ID=42728930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/001450 WO2010104309A2 (en) | 2009-03-13 | 2010-03-09 | Compositions for preventing or improving gastrointestinal diseases |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR101099004B1 (en) |
CN (2) | CN104248666A (en) |
BR (1) | BRPI1009105A2 (en) |
MY (1) | MY160409A (en) |
RU (1) | RU2500416C2 (en) |
UA (1) | UA99685C2 (en) |
WO (1) | WO2010104309A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622989A (en) * | 2015-01-15 | 2015-05-20 | 西安医学院 | Traditional Chinese medicine compound sterilizing agent and preparation method thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101263191B1 (en) * | 2010-05-06 | 2013-05-10 | 주식회사 사이그린 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
CN102600284A (en) * | 2011-01-21 | 2012-07-25 | 李艳娜 | Chinese medicinal enema for treating chronic colitis and rectitis |
KR20110056459A (en) * | 2011-04-04 | 2011-05-30 | 정필구 | Composition for prevention and improvement of periodontal disease |
CN102631432B (en) * | 2012-05-10 | 2013-09-11 | 黄炳炎 | Traditional Chinese medicine composition for preventing and curing sub-health |
CN102697926B (en) * | 2012-06-12 | 2013-11-27 | 查迅 | Chinese medicinal ointment for treating ulcerative colitis and preparation method thereof |
KR20140033998A (en) * | 2012-09-11 | 2014-03-19 | 씨제이제일제당 (주) | Composition for preventing or treating a gastrointestinal disorder, comprising saikosaponin a, berberine and licoisoflavone b |
CN103005063B (en) * | 2013-01-06 | 2014-02-12 | 江西省蚕桑茶叶研究所 | Gold bergamot bagged tea |
CN103223025A (en) * | 2013-05-21 | 2013-07-31 | 卫斌 | Medicine for treating gastritis and preparation method thereof |
CN103432276B (en) * | 2013-09-16 | 2015-03-25 | 河北科技师范学院 | Chinese herbal medicine oral liquid for treating acute paratyphoid fever of piglets |
KR102634898B1 (en) | 2015-11-06 | 2024-02-08 | 주식회사 제뉴원사이언스 | Composition for the prevention and treatment of inflammatory bowl disease comprising extract of Bupleurum falcatum Linne, Cimicifuga heracleifolia, Paeonia lactiflora and Aucklandia lappa Decne |
KR102434265B1 (en) * | 2017-09-20 | 2022-08-19 | 밍츄 리 | Chinese medicine for gastric ulcer treatment |
KR102428859B1 (en) * | 2020-05-29 | 2022-08-04 | 동성제약주식회사 | Pharmaceutical composition for oral administration to prevent or treat diseases of the digestive system with safety |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365198B1 (en) * | 2001-01-28 | 2002-04-02 | Gulf Pharmaceutical Industries | Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106678A (en) * | 1994-08-23 | 1995-08-16 | 路良宇 | Medicine for treatment of gastroenteritis and gastroenteritic ulcer and preparing process thereof |
US7198804B2 (en) * | 2002-04-12 | 2007-04-03 | Helixir Co., Ltd. | Crude drug composition for preventing and treating gastrointestinal dyskinetic diseases |
CN1579485B (en) * | 2004-03-16 | 2010-04-28 | 南京师范大学 | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method |
CN101209340B (en) * | 2006-12-25 | 2010-09-08 | 上海中医药大学附属岳阳中西医结合医院 | Chinese medicinal composition for treating gastroesophageal reflux disease |
CN101342282B (en) * | 2007-07-11 | 2011-08-10 | 深圳市齐旺投资有限公司 | Chinese medicinal composition for treating gastropathy and preparation method |
CN100569263C (en) * | 2007-11-07 | 2009-12-16 | 北京中科雍和医药技术有限公司 | A kind of pharmaceutical composition for the treatment of stomachache and preparation method thereof |
-
2009
- 2009-03-13 KR KR1020090021867A patent/KR101099004B1/en active IP Right Grant
-
2010
- 2010-03-09 MY MYPI2011004325A patent/MY160409A/en unknown
- 2010-03-09 BR BRPI1009105A patent/BRPI1009105A2/en not_active Application Discontinuation
- 2010-03-09 CN CN201410474873.6A patent/CN104248666A/en active Pending
- 2010-03-09 RU RU2011141504/15A patent/RU2500416C2/en active
- 2010-03-09 WO PCT/KR2010/001450 patent/WO2010104309A2/en active Application Filing
- 2010-03-09 CN CN2010800139052A patent/CN102365091A/en active Pending
- 2010-03-09 UA UAA201112018A patent/UA99685C2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365198B1 (en) * | 2001-01-28 | 2002-04-02 | Gulf Pharmaceutical Industries | Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids |
Non-Patent Citations (5)
Title |
---|
ALY, A.M. ET AL.: 'Licorice: A Possible Anti-inflammatory and Anti-ulcer Drug' AAPS PHARMSCITECH vol. 6, no. 1, 2005, pages E74 - E82 * |
HIRANO, H. ET AL.: 'Gastric-Mucous Membrane Protection Activity of Coptisine Derivatives' BIOLOGICAL & PHARMACEUTICAL BULLETIN vol. 24, no. 11, November 2001, pages 1277 - 1281 * |
LIU, R. ET AL.: 'Experimental study of the alleviated ethanol intoxication effect of Radix Bupleuri and Radix Scutellariae in Compatibility' PHARMACOLOGY AND CLINICS OF CHINEASE MATERIA MEDICA vol. 20, no. 4, 2004, pages 3 - 4 * |
OHTA, Y. ET AL.: 'Preventive Effect of Shigyaku-san on Progression of Acute Gastric Mucosal Lesions Induced by Compund 48/80, a Mast Cell Degranulator' RATS, PHYTOTHERAPY RESEARCH vol. 20, no. 4, April 2006, pages 256 - 262 * |
SHEN, X. ET AL.: 'Research and application of Radix Glycyrrhizae' ASIAN JOURNAL OF PHARMACODYNAMICS AND PHARMACOKINETICS vol. 7, no. 3, 2007, pages 181 - 200 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622989A (en) * | 2015-01-15 | 2015-05-20 | 西安医学院 | Traditional Chinese medicine compound sterilizing agent and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102365091A (en) | 2012-02-29 |
KR101099004B1 (en) | 2011-12-28 |
RU2500416C2 (en) | 2013-12-10 |
KR20100103305A (en) | 2010-09-27 |
WO2010104309A3 (en) | 2011-01-06 |
WO2010104309A9 (en) | 2011-02-24 |
RU2011141504A (en) | 2013-04-20 |
MY160409A (en) | 2017-03-15 |
BRPI1009105A2 (en) | 2016-03-08 |
CN104248666A (en) | 2014-12-31 |
UA99685C2 (en) | 2012-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010104309A2 (en) | Compositions for preventing or improving gastrointestinal diseases | |
KR100922987B1 (en) | A pharmaceutical composition having anti-inflammatory, analgesic, antipyretic, antioxidant and antihistamine effect and a method for preparation thereof | |
WO2015190760A1 (en) | Composition for preventing and treating non-alcoholic fatty liver diseases | |
WO2018174448A1 (en) | Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same | |
WO2011139118A2 (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
WO2019177428A1 (en) | Crude drug composition for preventing or treating respiratory diseases | |
WO2014042426A1 (en) | Composition comprising saikosaponin a, berberine, and licoisoflavone b for preventing or treating gastric diseases | |
WO2021071269A1 (en) | Composition for preventing or treating inflammatory bowel disease comprising extracts of complex herbal medicines | |
WO2016186349A2 (en) | Composition, containing quisaqualis indica extract, for preventing or treating prostatic hyperplasia | |
WO2016068607A1 (en) | Antitussive and expectorant composition containing, as active ingredient, mixture extract of coptidis rhizome and pelargonium sidoides | |
WO2022045418A1 (en) | Health functional food, comprising siberian chrysanthemum extract, for pain relief or antioxidation | |
WO2013122344A1 (en) | Pharmaceutical composition containing as active ingredient extract from bark of liriodendron tulipifera | |
WO2017146486A1 (en) | Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract | |
WO2013122345A1 (en) | Improved dosage form containing extract from bark of liriodendron tulipifera as active ingredient | |
WO2019124854A1 (en) | Composition for preventing or treating dry eye syndrome, containing mixed extract or fraction thereof | |
WO2021091164A1 (en) | Phamaceutical composition for preventing or treating obesity or allergy comprising rose extract as active ingredient | |
WO2012138076A2 (en) | Composition containing herbal extract mixture for prevention or treatment of gastrointestinal diseases | |
WO2018131780A1 (en) | Composition for preventing or treating gastritis or peptic ulcer | |
WO2014157811A1 (en) | Composition for remedying or treating rheumatoid arthritis and osteoarthritis | |
WO2018038293A1 (en) | Pharmaceutical composition containing sophora japonica l. extract as active ingredient for the prevention and treatment of neurodegenerative disorders | |
WO2017111429A1 (en) | Composition for treating dry eye syndrome, containing bog bilberry extract as active ingredient | |
WO2011078479A2 (en) | A composition comprising the extract of prunella vulgaris l. for preventing and treating adhd disease and the use thereof | |
WO2019245245A1 (en) | Pharmaceutical composition for preventing and treating liver damage comprising turmeric extract | |
WO2014126269A1 (en) | Pharmaceutical composition for improving male sexual function and for treating infertility | |
WO2020138974A1 (en) | Pharmaceutical composition containing magnolia obovata extract as active ingredient for prevention or treatment of anxiety disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080013905.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10751000 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011501823 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201112018 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2011141504 Country of ref document: RU Kind code of ref document: A |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/11/2011) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10751000 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1009105 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1009105 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110913 |